Timber Pharmaceuticals - Stock Price History | TMBR

Historical daily share price chart and data for Timber Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Timber Pharmaceuticals as of September 27, 2021 is 0.92.
  • The all-time high Timber Pharmaceuticals stock closing price was 1350.54 on June 11, 2015.
  • The Timber Pharmaceuticals 52-week high stock price is 3.65, which is 296.7% above the current share price.
  • The Timber Pharmaceuticals 52-week low stock price is 0.67, which is 27.2% below the current share price.
  • The average Timber Pharmaceuticals stock price for the last 52 weeks is 1.27.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Timber Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.7815 5.4934 10.4790 0.7200 0.7430 -85.40%
2019 13.9585 33.7635 43.2173 3.1116 5.0900 -84.28%
2018 58.0427 33.6134 103.3914 24.6699 32.3830 -2.09%
2017 117.4224 114.4058 255.1020 31.0324 33.0732 -70.53%
2016 245.8500 465.1861 585.2341 60.0240 112.2449 -75.39%
2015 529.8509 1200.4802 1350.5402 309.1236 456.1825 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.034B $0.000B
Timber Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company is initially engaged on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, tuberous sclerosis complex and localized scleroderma. Timber Pharmaceuticals Inc., formerly known as BioPharmX Corporation, is based in NJ, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29